HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

François Bertucci Selected Research

Adenocarcinoma

1/2022Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.
1/2021Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
1/2021LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.
1/2021Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.
4/2019XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.
11/2006FGFR1 and WT1 are markers of human prostate cancer progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


François Bertucci Research Topics

Disease

133Neoplasms (Cancer)
11/2022 - 10/2002
98Breast Neoplasms (Breast Cancer)
11/2022 - 04/2002
26Sarcoma (Soft Tissue Sarcoma)
03/2022 - 01/2012
22Neoplasm Metastasis (Metastasis)
04/2022 - 04/2002
20Inflammatory Breast Neoplasms
10/2021 - 12/2004
11Triple Negative Breast Neoplasms
06/2022 - 05/2013
6Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
03/2022 - 02/2011
6Adenocarcinoma
01/2022 - 11/2006
6Colorectal Neoplasms (Colorectal Cancer)
10/2021 - 06/2008
5Leiomyosarcoma
01/2022 - 11/2014
5Neutropenia
01/2022 - 03/2015
5Carcinogenesis
10/2021 - 03/2011
5Disease Progression
01/2021 - 09/2011
5Hypertension (High Blood Pressure)
01/2021 - 01/2016
5Carcinoma (Carcinomatosis)
07/2020 - 07/2003
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 03/2010
4Colonic Neoplasms (Colon Cancer)
01/2022 - 02/2004
4Asthenia
12/2021 - 12/2016
4Aggressive Fibromatosis (Desmoid)
01/2021 - 01/2013
4Hemangiosarcoma (Angiosarcoma)
10/2018 - 07/2012
3Circulating Neoplastic Cells
02/2022 - 06/2019
3Prostatic Neoplasms (Prostate Cancer)
01/2022 - 12/2014
3Thrombocytopenia (Thrombopenia)
01/2022 - 04/2015
3Liposarcoma
10/2020 - 12/2016
3Melanoma (Melanoma, Malignant)
07/2019 - 09/2007
3Synovial Sarcoma (Synovioma)
01/2018 - 05/2013
3Chordoma
01/2017 - 10/2011
2Febrile Neutropenia
01/2022 - 04/2015
2Pain (Aches)
01/2021 - 01/2017
2Margins of Excision
06/2020 - 10/2018
2Phyllodes Tumor (Cystosarcoma Phylloides)
06/2020 - 05/2020
2Genomic Instability
01/2019 - 12/2018
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2018 - 01/2005

Drug/Important Bio-Agent (IBA)

41DNA (Deoxyribonucleic Acid)IBA
05/2022 - 07/2002
22Proteins (Proteins, Gene)FDA Link
01/2022 - 10/2002
22Messenger RNA (mRNA)IBA
07/2021 - 05/2002
17Phenobarbital (Luminal)FDA Link
05/2021 - 08/2004
16Biomarkers (Surrogate Marker)IBA
09/2021 - 03/2003
14Hormones (Hormone)IBA
11/2022 - 10/2007
11Imatinib Mesylate (Gleevec)FDA Link
03/2022 - 02/2010
10AnthracyclinesIBA
06/2021 - 04/2002
10Biological ProductsIBA
01/2021 - 11/2005
8Immune Checkpoint InhibitorsIBA
03/2022 - 08/2017
8TrabectedinIBA
01/2022 - 02/2013
8Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 04/2012
8Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 07/2012
7Estrogen ReceptorsIBA
07/2021 - 01/2014
6Pharmaceutical PreparationsIBA
01/2022 - 03/2007
6Tyrosine Kinase InhibitorsIBA
01/2021 - 08/2012
6Trastuzumab (Herceptin)FDA Link
06/2020 - 12/2014
6Bevacizumab (Avastin)FDA Link
05/2019 - 09/2015
6LigandsIBA
03/2018 - 11/2011
5RNA (Ribonucleic Acid)IBA
01/2022 - 10/2002
5human ERBB2 proteinIBA
07/2021 - 01/2018
5regorafenibIBA
01/2021 - 12/2016
5Complementary DNA (cDNA)IBA
10/2002 - 04/2002
4Progesterone Receptors (Progesterone Receptor)IBA
07/2021 - 05/2013
4pazopanibFDA Link
01/2021 - 01/2016
4Poly(ADP-ribose) Polymerase InhibitorsIBA
11/2020 - 05/2011
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
07/2020 - 08/2012
4Monoclonal AntibodiesIBA
01/2020 - 06/2008
4Taxoids (Taxanes)IBA
10/2018 - 09/2011
4ErbB Receptors (EGF Receptor)IBA
01/2017 - 06/2008
4Phosphotransferases (Kinase)IBA
07/2011 - 02/2008
3CytokinesIBA
03/2022 - 05/2002
3CateninsIBA
01/2021 - 01/2018
3Carboplatin (JM8)FDA LinkGeneric
05/2020 - 01/2018
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2020 - 01/2014
3AntibodiesIBA
03/2020 - 01/2009
3Myristoylated Alanine-Rich C Kinase SubstrateIBA
01/2019 - 01/2017
3Small Interfering RNA (siRNA)IBA
01/2019 - 01/2015
3Docetaxel (Taxotere)FDA Link
04/2012 - 11/2009
2TOR Serine-Threonine KinasesIBA
01/2022 - 11/2017
2Antisense OligonucleotidesIBA
01/2022 - 07/2021
2EnzymesIBA
01/2022 - 07/2012
2amitraz (Taktic)IBA
01/2022 - 12/2021
270-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA
01/2022 - 12/2021
2taxaneIBA
01/2022 - 03/2011
2Peptides (Polypeptides)IBA
01/2021 - 01/2016
2erdafitinibIBA
12/2020 - 10/2020
2AntigensIBA
11/2020 - 03/2020
2Lapatinib (GW572016)FDA Link
06/2020 - 11/2017
2olaparibIBA
05/2020 - 01/2014
2Transcription Factors (Transcription Factor)IBA
04/2020 - 04/2016
2Cisplatin (Platino)FDA LinkGeneric
01/2020 - 01/2002
2Transaminases (Aminotransferases)IBA
01/2020 - 11/2017
2Cetuximab (Erbitux)FDA Link
12/2019 - 06/2008
2MicroRNAs (MicroRNA)IBA
06/2019 - 10/2015
2Poly (ADP-Ribose) Polymerase-1IBA
01/2019 - 05/2011
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 11/2016

Therapy/Procedure

50Therapeutics
05/2022 - 05/2002
41Drug Therapy (Chemotherapy)
01/2022 - 04/2002
12Adjuvant Chemotherapy
09/2021 - 04/2002
9Neoadjuvant Therapy
11/2022 - 11/2009
9Precision Medicine
05/2022 - 03/2012
6Radiotherapy
06/2020 - 11/2010
5Immunotherapy
05/2021 - 01/2017
3Stem Cell Transplantation
04/2017 - 01/2016
2Castration
01/2022 - 12/2014
2Laparotomy
05/2019 - 01/2012